Dr Jeremy Steele received his medical education at the University of London St George's Hospital Medical School. He proceeded to the Royal Marsden Hospital to train in cancer medicine after first training in acute general medical specialties and intensive care medicine. During this time, he conducted studies on lung cancer, brain tumours, and childhood leukaemia and received his Doctor of Medicine degree for his work on cancer biology. He then undertook oncology training at St. Bartholomew's Hospital and the Royal London Hospital in London's East End. In 1999, he became a visiting fellow at Harvard Medical School's thoracic oncology centre in Boston.

Dr Steele also led one of the first effective clinical studies of mesothelioma therapy in East London, the centre of the city's malignant mesothelioma epidemic. He joined Barts in 2002 as a consultant oncologist with a special interest in lung cancer and mesothelioma.

Dr Steele is renowned in the UK as a lung cancer specialist, and he is globally recognised as an expert in the diagnosis and treatment of malignant mesothelioma. He is the secretary of the International Mesothelioma Group (iMig), located in Chicago, and the chairman of the Mesothelioma UK Charitable Trust's advisory board. He also has a lengthy history of patient advocacy and has successfully lobbied the UK Government for the availability of novel cancer medicines.

Diseases, Medical Tests and Treatments

• Malignant mesothelioma (pleural and peritoneal)
• Immunotherapy for mesothelioma and lung cancer
• Maximisation of quality of life
• Patient-centred cancer care
• Malignant mesothelioma (pleural and peritoneal)
• Immunotherapy for mesothelioma and lung cancer
• Maximisation of quality of life
• Patient-centred cancer care